MIDNOR-TIA – a Study of 600 Patients With Transient Ischemic Attack

Overview

Patients with a transient ischemic attack (TIA) are at high risk of stroke. Rapid assessment and treatment can reduce the risk. Several international guidelines recommend a test, the ABCD2 score, to identify TIA patients with low and high risk for stroke. The main purpose of this study is to investigate stroke risk after TIA in both short (1 week) and long term (3 months/1 year), and to assess whether the ABCD2 score ('Age, blood pressure, clinical features, duration of TIA, diabetes score) is an adequate tool for predicting stroke risk. Secondary aims are to explore whether adopting imaging modalities (ultrasound, MRI) and biological markers of blood into a risk score could improve the predictive value of the ABCD2 score and still be feasible in a daily clinical practice. Further on overall risk factors in TIA patients, and the incidence of other vascular events will be studied. A substudy designed as a randomised controlled trial evaluates pharmaceutical counseling in a subset of participants. Cost-benefit analysis, and a long-term follow-up (5 years) is planned.

Full Title of Study: “MIDNOR-TIA – a Prospective Cohort Study of 600 TIA Patients in Central Norway”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: July 2014

Arms, Groups and Cohorts

  • TIA in last 2 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Number of patients presenting with stroke within 1 week after transient ischemic attack
    • Time Frame: 1 week
    • Measured by using data from the Norwegian Stroke Registry

Secondary Measures

  • Number of patients presenting with stroke within 3 months after transient ischemic attack
    • Time Frame: 3 months
    • Measured by using data from the Norwegian Stroke Registry
  • Correlation between the ABCD2 score and the incidence of stroke within 1 week after transient ischemic attack
    • Time Frame: 1 week
    • Measured by comparing the ABCD2 score and the incidence of stroke within 1 week after transient ischemic attack based on data from the Norwegian Stroke Registry
  • Correlation between the ABCD2 score and the incidence of stroke within 3 months after transient ischemic attack
    • Time Frame: 3 months
    • Measured by comparing the ABCD2 score and the incidence of stroke within 3 months after transient ischemic attack based on data from the Norwegian Stroke Registry
  • Incidence of other vascular events within 1 week after transient ischemic attack
    • Time Frame: 1 week
    • Measured by using data from national health registries
  • Cost-benefit analysis
    • Time Frame: 1 year
    • Economic analysis that compares the costs of admission to hospital versus outpatient assessment of patients who have had transient ischemic attacks
  • Number of patients presenting with stroke within 1 year after transient ischemic attack
    • Time Frame: 1 year
    • Measured by using data from the Norwegian Stroke Registry
  • Correlation between the ABCD2 score and the incidence of stroke within 1 year after transient ischemic attack
    • Time Frame: 1 year
    • Measured by comparing the ABCD2 score and the incidence of stroke within 1 year after transient ischemic attack based on data from the Norwegian Stroke Registry
  • Incidence of other vascular events within 3 months after transient ischemic attack
    • Time Frame: 3 months
    • Measured by using data from national health registries
  • Incidence of other vascular events within 1 year after transient ischemic attack
    • Time Frame: 1 year
    • Measured by using data from national health registries

Participating in This Clinical Trial

Inclusion Criteria

  • Probable or possible transient ischemic attack
  • Residing in Central Norway
  • Examined within 2 weeks after the onset of symptoms
  • Modified Rankin Scale 3 or less and living at home
  • Informed consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Norwegian University of Science and Technology
  • Collaborator
    • St. Olavs Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bent Indredavik, PhD, Prof, Study Director, Norwegian University of Science and Technology

Citations Reporting on Results

Ildstad F, Ellekjaer H, Fjaertoft H, Indredavik B. MIDNOR TIA – a prospective cohort study of 586 patients, baseline data from a subgroup of 363 patients examined with diffusion-weighted imaging. International Journal of Stroke 10(suppl 2):242, 2015 (Meeting Abstract ESOC-1527)

Ildstad F, Ellekjær H, Wethal T, Lydersen S, Sund JK, Fjærtoft H, Schüler S, Horn JW, Bråthen G, Midtsæther AG, Morsund ÅH, Lillebø ML, Seljeseth YM, Indredavik B. Stroke risk after transient ischemic attack in a Norwegian prospective cohort. BMC Neurol. 2019 Jan 3;19(1):2. doi: 10.1186/s12883-018-1225-y.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.